Integrase Inhibitors Fare Well in HIV Patients with Baseline NNRTI Resistance

In a retrospective study of treatment-naive patients with isolated resistance to nonnucleoside reverse transcriptase inhibitors, integrase inhibitor–based regimens compared favorably with boosted protease inhibitor–based regimens.

For people newly infected with HIV, resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) is the most common form of transmitted drug resistance. Patients with baseline NNRTI resistance generally receive boosted protease inhibitor (bPI)–based antiretroviral therapy (ART). To learn more about ART response in patients who receive integrase inhibitor–based therapy but have NNRTI resistance, researchers retrospectively studied data from 3245 treatment-naive patients (87% men; median viral load, 4.5 log copies/mL; median CD4 count, 343 cells/mm³) in a large HIV-care program.

Of 131 patients (4%) with baseline isolated NNRTI resistance, 122 received standard ART regimens comprising two nucleoside reverse transcriptase inhibitors (N…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Integrase Inhibitors Fare Well in HIV Patients with Baseline NNRTI Resistance

Topics

Reviewing Author